New radiation combo shows promise in tough brain cancer battle

NCT ID NCT07100730

Recruiting now Disease control Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests a new drug, TLX101-Tx, that delivers radiation directly to glioblastoma cells. It is combined with standard chemotherapy (lomustine) and compared to chemotherapy alone in 50 adults whose brain cancer has returned after initial treatment. The goal is to see if the combination can better control the tumor and improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma brain cancer central nervous system cancer glioblastoma neoplasm Neoplasm Recurrence, Local neoplastic disease or syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA (GBM) GLIOBLASTOMA MULTIFORM GLIOBLASTOMA MULTIFORME (GBM) WHO GRADE IV GLIOBLASTOMA MULTIFORME, ADULT NEOPLASTIC DISEASE

Contacts and locations

Locations

Austin Health
RECRUITING

Melbourne, Victoria, Australia
Chu of Liège
RECRUITING

Liège, Belgium
Gold Coast University Hospital
RECRUITING

Gold Coast, Queensland, Australia
Johannes Kepler University
RECRUITING

Linz, Austria
Royal Adelaide Hospital
NOT_YET_RECRUITING

Adelaide, Australia
Sir Charles Gairdner Hospital
RECRUITING

Perth, Western Australia, Australia
The Netherlands Cancer Institute (NKI)
NOT_YET_RECRUITING

Amsterdam, Netherlands
UMC Utrecht
RECRUITING

Utrecht, Netherlands
UZ Leuven
RECRUITING

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.